Y-mAbs Therapeutics, Inc.
YMAB
$8.53
$0.010.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.36% | 4.88% | 13.41% | -9.74% | 9.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.36% | 4.88% | 13.41% | -9.74% | 9.86% |
| Cost of Revenue | -10.02% | 39.78% | 284.60% | -15.01% | -35.17% |
| Gross Profit | -15.02% | 0.67% | -12.53% | -8.96% | 22.87% |
| SG&A Expenses | -34.17% | 9.81% | 5.01% | 26.09% | 52.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.89% | -1.18% | 16.17% | -6.71% | 16.49% |
| Operating Income | 42.75% | 18.66% | -36.39% | -1.30% | -35.53% |
| Income Before Tax | 64.67% | 19.76% | -851.07% | 12.01% | -49.42% |
| Income Tax Expenses | -93.00% | -96.88% | -485.64% | 85.03% | -44.13% |
| Earnings from Continuing Operations | 64.98% | 21.62% | -587.25% | 9.67% | -46.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.98% | 21.62% | -587.25% | 9.67% | -46.76% |
| EBIT | 42.75% | 18.66% | -36.39% | -1.30% | -35.53% |
| EBITDA | 42.39% | 17.80% | -40.26% | -1.95% | -37.68% |
| EPS Basic | 65.97% | 23.91% | -569.47% | 11.71% | -45.60% |
| Normalized Basic EPS | 65.67% | 36.04% | -628.95% | 23.27% | -48.29% |
| EPS Diluted | 65.97% | 23.91% | -573.01% | 11.71% | -45.60% |
| Normalized Diluted EPS | 65.67% | 36.04% | -628.95% | 23.27% | -48.29% |
| Average Basic Shares Outstanding | 2.94% | 3.03% | 2.86% | 2.31% | 0.82% |
| Average Diluted Shares Outstanding | 2.94% | 3.03% | 2.86% | 2.31% | 0.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |